Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Tim Cruise who wrote (201)	12/1/1999 1:34:00 PM
From: thebeach	Respond to of 356

Sure can Tim,here you go and don't fret the other issue.We know we have a real winner and thats all that matters.Have a great day. www2.cdn-news.com NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS FOR: PROCYON BIOPHARMA INC. CDNX SYMBOL: PBP DECEMBER 1, 1999 Procyon Biopharma Inc. Appoints Vice-president Business Development and Licensing MONTREAL, QUEBEC--Procyon BioPharma Inc. ("Procyon") announced today the appointment of Dr. Naveen N. Anand as Vice-President, Business Development and Licensing, further strengthening the Company's management team following its recent decision to move to Montreal. Prior to this appointment, Dr. Anand was Manager, New Products and New Markets Development with the Oncology Business Unit of Pasteur Merieux Connaught Canada where he also worked as a research scientist and manager of technology evaluations. Dr. Anand holds a Ph.D. in Natural Sciences from the University of Cambridge in England as well as Bachelors and Masters degrees in pharmacy from Punjab University in India and an MBA from the University of Toronto. Dr. Anand has also worked as a research associate with the National Research Council of Canada. "We are very pleased to have been able to attract a person of Dr. Anand's calibre to the Procyon team. His training in both science and business and his extensive experience with the Canadian arm of one of the world's leading pharmaceutical companies gives him exactly the background we need to develop and license our technologies around the world," stated Hans J. Mader, Procyon's President and CEO. "His addition to our management team along with the recent appointment to our Board of Dr. Max Link, provide us with excellent connections to big pharma here in Canada and worldwide," he added. "Dr. Link is the former Chairman and CEO of Sandoz Pharma Ltd. and the former CEO of Corange, Ltd. He is presently Chairman of Cell Therapeutics and CytRx Corporation, both NASDAQ listed companies, and is a director of a number of other companies including Protein Design Labs and Human Genome Sciences." During the month of November, Procyon completed a $3 million private placement with key Quebec-based venture capital firms, T2C2 and Innovatech du Grand Montreal, as well as with European and other investors, Company directors, employees and shareholders. Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. Procyon also has two late-stage products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the CDNX (formerly the Alberta Stock Exchange) under the ticker symbol, PBP. The CDNX has neither approved or disapproved the information contained in this release. -30-

To: Tim Cruise who wrote (201)	12/2/1999 10:09:00 AM
From: Abbeydale	Read Replies (2) \| Respond to of 356

Gosh, Tim... I guess you really didn't mean what you said in your PM apology that I just responded to before reading this. You fellas ought to spend more time touting the real benefits behind the company and analysing the pros and cons for the many,many lurkers and posters reading this thread than wasting time slamming us... great little "club" you guys have here... always nice to feel "welcomed" by company "regulars" on a thread... reflects on the company. Well, if I am contrarian (read: always wrong), then you had better sell, because I bought a bunch yesterday in the mid $1.30's... I'm outta here.. A